A5028033679- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Endometrial and Cervical Cancer Treatments
- HER2/EGFR in Cancer Research
- Intraperitoneal and Appendiceal Malignancies
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastrointestinal Tumor Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Breast Cancer Treatment Studies
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Occupational and environmental lung diseases
- Pancreatic and Hepatic Oncology Research
- Advanced Breast Cancer Therapies
- Cervical Cancer and HPV Research
- Colorectal and Anal Carcinomas
- Pleural and Pulmonary Diseases
Instituto Alexander Fleming
2007-2024
National Taiwan University Hospital
2009-2018
Kindai University
2018
National Yang Ming Chiao Tung University
2018
Taipei Veterans General Hospital
2018
Shizuoka Cancer Center
2018
National Cheng Kung University Hospital
2018
Eli Lilly (United States)
2007-2017
Eli Lilly (India)
2017
Universidad Abierta Interamericana
2010-2017
To determine whether addition of gemcitabine to concurrent cisplatin chemoradiotherapy and as adjuvant chemotherapy with improves progression-free survival (PFS) at 3 years compared current standard care in locally advanced cervical cancer.Eligible chemotherapy- radiotherapy-naive patients stage IIB IVA disease Karnofsky performance score ≥ 70 were randomly assigned arm A (cisplatin 40 mg/m(2) 125 weekly for 6 weeks external-beam radiotherapy [XRT] 50.4 Gy 28 fractions, followed by...
Ovarian cancer (OC) patients experiencing progressive disease (PD) within 6 months of platinum-based therapy in the primary setting are considered platinum resistant (Pt-R). Currently, pegylated liposomal doxorubicin (PLD) is a standard care for treatment recurrent Pt-R disease. On basis promising phase II results, gemcitabine was compared with PLD efficacy and safety taxane-pretreated OC patients.Patients (n = 195) were randomly assigned to either 1,000 mg/m2 (days 1 8; every 21 days) or 50...
To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with monotherapy, in patients advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations.Chemotherapy-naïve for NSCLC from China, Japan, Korea, Taiwan (35 sites) advanced, EGFR-mutant, NS were randomly assigned (2:1; computer-generated, interactive voice response) open-label (500 mg/m(2) on day 1 every 21-day cycle) plus...
IntroductionClinical studies have shown that a combination of tyrosine kinase inhibitor (TKI) and pemetrexed overcame acquired resistance to epidermal growth factor receptor (EGFR) TKI in NSCLC. Previously, pemetrexed+gefintib (P+G) had improved progression-free survival (PFS) compared with gefitinib. We present OS, updated PFS, biomarker analysis, safety P+G versus gefitinib.MethodsThis was phase 2, multicenter, randomized study conducted East Asian patients advanced nonsquamous NSCLC EGFR...
East Asia has higher gastric cancer incidence and mortality rates than other regions. We present a subgroup analysis of Asians in the positive study RAINBOW.Patients with advanced or gastroesophageal junction adenocarcinoma previously treated platinum fluoropyrimidine received ramucirumab 8 mg/kg placebo on days 1 15 plus paclitaxel 80 mg/m(2) 1, 8, 28-day cycle.Of 665 intention-to-treat patients, 223 were Asian. Median overall survival was 12.1 months for 10.5 (hazard ratio: 0.986, 95%...
Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated (ALD) are among the leading indications for transplantation (LT). The definition of metabolic dysfunction- (MetALD) identifies individuals with MASLD who consume moderate levels alcohol, representing a severe phenotype within (SLD) spectrum. Patients MetALD face higher risks post-LT complications, including syndrome, graft steatosis, fibrosis. Despite rising prevalence due to increasing obesity alcohol...
IntroductionThe primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and monotherapy (G) patients with advanced nonsquamous non–small cell lung cancer (NSCLC) unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. This report describes final overall (OS)...